{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:41:55Z","timestamp":1793040115399,"version":"4.5.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005892","name":"China Academy of Chinese Medical Sciences","doi-asserted-by":"publisher","award":["No.CI2021A00701-3; No.CI2021A05503; No.CI2021B003; No. 2020YJSZX-2"],"award-info":[{"award-number":["No.CI2021A00701-3; No.CI2021A05503; No.CI2021B003; No. 2020YJSZX-2"]}],"id":[{"id":"10.13039\/501100005892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-025-04872-4","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T02:19:35Z","timestamp":1745374775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Berberine and health outcomes: an overview of systematic reviews"],"prefix":"10.1186","volume":"25","author":[{"given":"Lanjun","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyang","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"4872_CR1","unstructured":"Collaborators GCD. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet; 2024."},{"key":"4872_CR2","doi-asserted-by":"crossref","unstructured":"Fontana L. From chronic disease to chronic health: the evolving role of Doctors in the 21st century. Eur Heart J 2024.","DOI":"10.1093\/eurheartj\/ehae173"},{"issue":"1","key":"4872_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pbc.21798","volume":"52","author":"A Hamidah","year":"2009","unstructured":"Hamidah A, Rustam ZA, Tamil AM, Zarina LA, Zulkifli ZS, Jamal R. Prevalence and parental perceptions of complementary and alternative medicine use by children with cancer in a multi-ethnic Southeast Asian population. Pediatr Blood Cancer. 2009;52(1):70\u20134.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"4872_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.lab.2005.11.011","volume":"147","author":"K Wojcikowski","year":"2006","unstructured":"Wojcikowski K, Johnson DW, Gobe G. Herbs or natural substances as complementary therapies for chronic kidney disease: ideas for future studies. J Lab Clin Med. 2006;147(4):160\u20136.","journal-title":"J Lab Clin Med"},{"issue":"1","key":"4872_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5414\/CNP92S108","volume":"93","author":"GC Gobe","year":"2020","unstructured":"Gobe GC, Wojcikowski K. Nontraditional (non-Western pharmaceutical) treatments for chronic kidney disease. Clin Nephrol. 2020;93(1):49\u201354.","journal-title":"Clin Nephrol"},{"key":"4872_CR6","doi-asserted-by":"crossref","unstructured":"Waltenberger B, Mocan A, \u0160mejkal K, Heiss EH, Atanasov AG. Natural products to counteract the epidemic of cardiovascular and metabolic disorders. Molecules 2016, 21(6).","DOI":"10.3390\/molecules21060807"},{"issue":"1","key":"4872_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","volume":"15","author":"M Tintore","year":"2019","unstructured":"Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol. 2019;15(1):53\u20138.","journal-title":"Nat Rev Neurol"},{"key":"4872_CR8","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Yoldi MJ. Anti-Inflammatory and antioxidant properties of plant extracts. Antioxid (Basel) 2021, 10(6).","DOI":"10.3390\/antiox10060921"},{"key":"4872_CR9","doi-asserted-by":"crossref","unstructured":"Rapa SF, Di Iorio BR, Campiglia P, Heidland A, Marzocco S. Inflammation and oxidative stress in chronic kidney Disease-Potential therapeutic role of minerals, vitamins and Plant-Derived metabolites. Int J Mol Sci 2019, 21(1).","DOI":"10.3390\/ijms21010263"},{"issue":"12","key":"4872_CR10","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1038\/s41401-022-00983-7","volume":"43","author":"C Li","year":"2022","unstructured":"Li C, Jia WW, Yang JL, Cheng C, Olaleye OE. Multi-compound and drug-combination Pharmacokinetic research on Chinese herbal medicines. Acta Pharmacol Sin. 2022;43(12):3080\u201395.","journal-title":"Acta Pharmacol Sin"},{"key":"4872_CR11","doi-asserted-by":"publisher","first-page":"154531","DOI":"10.1016\/j.phymed.2022.154531","volume":"108","author":"G Yan","year":"2023","unstructured":"Yan G, Chang T, Zhao Y, Yu M, Mi J, Wang G, Wang X, Liao X. The effects of ophiocordyceps sinensis combined with ACEI\/ARB on diabetic kidney disease: A systematic review and meta-analysis. Phytomedicine. 2023;108:154531.","journal-title":"Phytomedicine"},{"issue":"11","key":"4872_CR12","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/ptr.6743","volume":"34","author":"M Gu","year":"2020","unstructured":"Gu M, Song H, Li Y, Jiang Y, Zhang Y, Tang Z, Ji G, Huang C. Extract of schisandra chinensis fruit protects against metabolic dysfunction in high-fat diet induced obese mice via FXR activation. Phytother Res. 2020;34(11):3063\u201377.","journal-title":"Phytother Res"},{"key":"4872_CR13","doi-asserted-by":"publisher","first-page":"155418","DOI":"10.1016\/j.phymed.2024.155418","volume":"128","author":"H Ma","year":"2024","unstructured":"Ma H, Yue GG, Lee JK, Gao S, Yuen KK, Cheng W, Li X, Lau CB. Scutellarin, a flavonoid compound from scutellaria Barbata, suppresses growth of breast cancer stem cells in vitro and in tumor-bearing mice. Phytomedicine. 2024;128:155418.","journal-title":"Phytomedicine"},{"key":"4872_CR14","doi-asserted-by":"publisher","first-page":"155563","DOI":"10.1016\/j.phymed.2024.155563","volume":"129","author":"H Peng","year":"2024","unstructured":"Peng H, Lin X, Wang Y, Chen J, Zhao Q, Chen S, Cheng Q, Chen C, Sang T, Zhou H, et al. Epigallocatechin gallate suppresses mitotic clonal expansion and adipogenic differentiation of preadipocytes through impeding JAK2\/STAT3-mediated transcriptional cascades. Phytomedicine. 2024;129:155563.","journal-title":"Phytomedicine"},{"key":"4872_CR15","first-page":"3151936","volume":"2022","author":"H Li","year":"2022","unstructured":"Li H, Hu R, Xu S, Dai Z, Wu X, Hu J, Liao X. Tripterygium wilfordii Hook. F. Preparations F.r rheumatoid arthritis: an overview of systematic reviews. Evid Based Complement Alternat Med. 2022;2022:3151936.","journal-title":"Evid Based Complement Alternat Med"},{"key":"4872_CR16","doi-asserted-by":"publisher","first-page":"155705","DOI":"10.1016\/j.phymed.2024.155705","volume":"130","author":"X Guo","year":"2024","unstructured":"Guo X, Wen S, Wang J, Zeng X, Yu H, Chen Y, Zhu X, Xu L. Senolytic combination of dasatinib and Quercetin attenuates renal damage in diabetic kidney disease. Phytomedicine. 2024;130:155705.","journal-title":"Phytomedicine"},{"key":"4872_CR17","doi-asserted-by":"publisher","first-page":"155467","DOI":"10.1016\/j.phymed.2024.155467","volume":"127","author":"C Liu","year":"2024","unstructured":"Liu C, Huang J, Qiu J, Jiang H, Liang S, Su Y, Lin J, Zheng J. Quercitrin improves cardiac remodeling following myocardial infarction by regulating macrophage polarization and metabolic reprogramming. Phytomedicine. 2024;127:155467.","journal-title":"Phytomedicine"},{"key":"4872_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13020-018-0171-3","volume":"13","author":"FC Meng","year":"2018","unstructured":"Meng FC, Wu ZF, Yin ZQ, Lin LG, Wang R, Zhang QW. Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and Pharmacological activity. Chin Med. 2018;13:13.","journal-title":"Chin Med"},{"key":"4872_CR19","doi-asserted-by":"publisher","first-page":"774795","DOI":"10.3389\/fphar.2021.774795","volume":"12","author":"J Meng","year":"2021","unstructured":"Meng J, Qiu S, Zhang L, You M, Xing H, Zhu J. Berberine alleviate Cisplatin-Induced peripheral neuropathy by modulating inflammation signal via TRPV1. Front Pharmacol. 2021;12:774795.","journal-title":"Front Pharmacol"},{"key":"4872_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1746-4269-2-27","volume":"2","author":"RM Kunwar","year":"2006","unstructured":"Kunwar RM, Nepal BK, Kshhetri HB, Rai SK, Bussmann RW. Ethnomedicine in Himalaya: a case study from Dolpa, Humla, Jumla and Mustang districts of Nepal. J Ethnobiol Ethnomed. 2006;2:27.","journal-title":"J Ethnobiol Ethnomed"},{"key":"4872_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-3-319-41334-1_2","volume":"928","author":"AF Cicero","year":"2016","unstructured":"Cicero AF, Baggioni A. Berberine and its role in chronic disease. Adv Exp Med Biol. 2016;928:27\u201345.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"4872_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.metabol.2009.07.029","volume":"59","author":"H Zhang","year":"2010","unstructured":"Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, Wang SK, Zhou ZX, Song DQ, Wang YM, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010;59(2):285\u201392.","journal-title":"Metabolism"},{"issue":"5","key":"4872_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-023-01841-4","volume":"83","author":"JE Blais","year":"2023","unstructured":"Blais JE, Huang X, Zhao JV. Overall and Sex-Specific effect of Berberine for the treatment of dyslipidemia in adults: A systematic review and Meta-Analysis of randomized Placebo-Controlled trials. Drugs. 2023;83(5):403\u201327.","journal-title":"Drugs"},{"issue":"3","key":"4872_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/pcn.13323","volume":"76","author":"M Chan","year":"2022","unstructured":"Chan M, Qin Z, Man SC, Lam M, Lai WH, Ng RMK, Lee CK, Wong TL, Lee EHM, Wong HK, et al. Adjunctive Berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial. Psychiatry Clin Neurosci. 2022;76(3):77\u201385.","journal-title":"Psychiatry Clin Neurosci"},{"key":"4872_CR25","doi-asserted-by":"publisher","first-page":"110137","DOI":"10.1016\/j.biopha.2020.110137","volume":"127","author":"Z Ilyas","year":"2020","unstructured":"Ilyas Z, Perna S, Al-Thawadi S, Alalwan TA, Riva A, Petrangolini G, Gasparri C, Infantino V, Peroni G, Rondanelli M. The effect of Berberine on weight loss in order to prevent obesity: A systematic review. Biomed Pharmacother. 2020;127:110137.","journal-title":"Biomed Pharmacother"},{"key":"4872_CR26","doi-asserted-by":"publisher","first-page":"154716","DOI":"10.1016\/j.phymed.2023.154716","volume":"112","author":"L Yang","year":"2023","unstructured":"Yang L, Zhu W, Zhang X, Zhou X, Wu W, Shen T. Efficacy and safety of Berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2023;112:154716.","journal-title":"Phytomedicine"},{"issue":"1","key":"4872_CR27","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","volume":"12","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Gunn N, Neff GW, Kohli A, Liu L, Flyer A, Goldkind L, Di Bisceglie AM. A phase 2, proof of concept, randomised controlled trial of Berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun. 2021;12(1):5503.","journal-title":"Nat Commun"},{"issue":"14","key":"4872_CR28","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1097\/CM9.0000000000002696","volume":"136","author":"S Chen","year":"2023","unstructured":"Chen S, Shen W, Liu Y, Dong Q, Shi Y. Efficacy and safety of triple therapy containing Berberine, amoxicillin, and Vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial. Chin Med J (Engl). 2023;136(14):1690\u20138.","journal-title":"Chin Med J (Engl)"},{"key":"4872_CR29","doi-asserted-by":"publisher","first-page":"155456","DOI":"10.1016\/j.phymed.2024.155456","volume":"128","author":"S He","year":"2024","unstructured":"He S, Li H, Zhang Q, Zhao W, Li W, Dai C, Li B, Cheng J, Wu S, Zhou Z, et al. Berberine alleviates inflammation in polycystic ovary syndrome by inhibiting hyaluronan synthase 2 expression. Phytomedicine. 2024;128:155456.","journal-title":"Phytomedicine"},{"issue":"4","key":"4872_CR30","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.dsx.2019.07.003","volume":"13","author":"R Nepomuceno","year":"2019","unstructured":"Nepomuceno R, Vallerini BF, da Silva RL, Corbi SCT, Bastos AS, Dos Santos RA, Takahashi CS, Orrico SRP, Scarel-Caminaga RM. Systemic expression of genes related to inflammation and lipid metabolism in patients with dyslipidemia, type 2 diabetes mellitus and chronic periodontitis. Diabetes Metab Syndr. 2019;13(4):2715\u201322.","journal-title":"Diabetes Metab Syndr"},{"issue":"4","key":"4872_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.plipres.2011.04.002","volume":"50","author":"JE McLaren","year":"2011","unstructured":"McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res. 2011;50(4):331\u201347.","journal-title":"Prog Lipid Res"},{"issue":"Suppl 1","key":"4872_CR32","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1097\/01.ASN.0000093237.00846.78","volume":"15","author":"J Segura","year":"2004","unstructured":"Segura J, Campo C, Rold\u00e1n C, Christiansen H, Vigil L, Garc\u00eda-Robles R, Rodicio JL, Ruilope LM. Hypertensive renal damage in metabolic syndrome is associated with glucose metabolism disturbances. J Am Soc Nephrol. 2004;15(Suppl 1):S37\u201342.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4872_CR33","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2015","unstructured":"Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62(3):720\u201333.","journal-title":"J Hepatol"},{"issue":"2","key":"4872_CR34","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1053\/j.gastro.2020.10.057","volume":"160","author":"J Aron-Wisnewsky","year":"2021","unstructured":"Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Cl\u00e9ment K. Metabolism and metabolic disorders and the microbiome: the intestinal microbiota associated with obesity, lipid metabolism, and metabolic Health-Pathophysiology and therapeutic strategies. Gastroenterology. 2021;160(2):573\u201399.","journal-title":"Gastroenterology"},{"issue":"50","key":"4872_CR35","doi-asserted-by":"publisher","first-page":"20073","DOI":"10.1021\/acs.jafc.3c04811","volume":"71","author":"Y Zhong","year":"2023","unstructured":"Zhong Y, Xiao Q, Huang J, Yu S, Chen L, Wan Q, Zhang Z, Luo L, Song L, Zhao H, et al. Ginsenoside Rg1 alleviates ulcerative colitis in obese mice by regulating the gut Microbiota-Lipid Metabolism-Th1\/Th2\/Th17 cells axis. J Agric Food Chem. 2023;71(50):20073\u201391.","journal-title":"J Agric Food Chem"},{"key":"4872_CR36","doi-asserted-by":"publisher","first-page":"870407","DOI":"10.3389\/fphar.2022.870407","volume":"13","author":"X Fang","year":"2022","unstructured":"Fang X, Wu H, Wang X, Lian F, Li M, Miao R, Wei J, Tian J. Modulation of gut microbiota and metabolites by Berberine in treating mice with disturbances in glucose and lipid metabolism. Front Pharmacol. 2022;13:870407.","journal-title":"Front Pharmacol"},{"issue":"3","key":"4872_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2468-1253(19)30409-1","volume":"5","author":"YX Chen","year":"2020","unstructured":"Chen YX, Gao QY, Zou TH, Wang BM, Liu SD, Sheng JQ, Ren JL, Zou XP, Liu ZJ, Song YY, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol. 2020;5(3):267\u201375.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"4872_CR38","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1038\/s41467-020-18414-8","volume":"11","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Gu Y, Ren H, Wang S, Zhong H, Zhao X, Ma J, Gu X, Xue Y, Huang S, et al. Gut microbiome-related effects of Berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020;11(1):5015.","journal-title":"Nat Commun"},{"key":"4872_CR39","doi-asserted-by":"publisher","first-page":"1015045","DOI":"10.3389\/fphar.2022.1015045","volume":"13","author":"W Xie","year":"2022","unstructured":"Xie W, Su F, Wang G, Peng Z, Xu Y, Zhang Y, Xu N, Hou K, Hu Z, Chen Y, et al. Glucose-lowering effect of Berberine on type 2 diabetes: A systematic review and meta-analysis. Front Pharmacol. 2022;13:1015045.","journal-title":"Front Pharmacol"},{"key":"4872_CR40","doi-asserted-by":"crossref","unstructured":"Wei X, Wang C, Hao S, Song H, Yang L. The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Evid Based Complement Alternat Med 2016, 2016:3593951.","DOI":"10.1155\/2016\/3593951"},{"key":"4872_CR41","doi-asserted-by":"publisher","first-page":"e070849","DOI":"10.1136\/bmj-2022-070849","volume":"378","author":"M Gates","year":"2022","unstructured":"Gates M, Gates A, Pieper D, Fernandes RM, Tricco AC, Moher D, Brennan SE, Li T, Pollock M, Lunny C, et al. Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. BMJ. 2022;378:e070849.","journal-title":"BMJ"},{"key":"4872_CR42","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"4872_CR43","doi-asserted-by":"publisher","first-page":"155293","DOI":"10.1016\/j.phymed.2023.155293","volume":"125","author":"G Chen","year":"2024","unstructured":"Chen G, Lu J, Li B, Zhao M, Liu D, Yang Z, Liu F. Efficacy and safety of Shenqi Fuzheng injection combined with chemotherapy for cancer: an overview of systematic reviews. Phytomedicine. 2024;125:155293.","journal-title":"Phytomedicine"},{"key":"4872_CR44","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.","journal-title":"BMJ"},{"issue":"4","key":"4872_CR45","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"4872_CR46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jrsm.1557","volume":"13","author":"J P\u00e9rez-Bracchiglione","year":"2022","unstructured":"P\u00e9rez-Bracchiglione J, Meza N, Bangdiwala SI, Ni\u00f1o de Guzm\u00e1n E, Urr\u00fatia G, Bonfill X, Madrid E. Graphical representation of overlap for overviews: GROOVE tool. Res Synth Methods. 2022;13(3):381\u20138.","journal-title":"Res Synth Methods"},{"issue":"4","key":"4872_CR47","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jclinepi.2013.11.007","volume":"67","author":"D Pieper","year":"2014","unstructured":"Pieper D, Antoine SL, Mathes T, Neugebauer EA, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014;67(4):368\u201375.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"4872_CR48","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1002\/ptr.7998","volume":"37","author":"Y Vahedi-Mazdabadi","year":"2023","unstructured":"Vahedi-Mazdabadi Y, Shahinfar H, Toushih M, Shidfar F. Effects of Berberine and barberry on selected inflammatory biomarkers in adults: A systematic review and dose-response meta-analysis of randomized clinical trials. Phytother Res. 2023;37(12):5541\u201357.","journal-title":"Phytother Res"},{"key":"4872_CR49","first-page":"0055","volume":"6","author":"Y Lin","year":"2023","unstructured":"Lin Y, Xu X, Luo T, Zhou Y. Meta analysis of the effects of Berberine on glycolipid metabolism and Proinflammatory cytokines in schizophrenia. Med Health Vol. 2023;6:0055\u201361.","journal-title":"Med Health Vol"},{"key":"4872_CR50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jclinepi.2019.09.025","volume":"118","author":"C Lunny","year":"2020","unstructured":"Lunny C, Brennan SE, Reid J, McDonald S, McKenzie JE. Overviews of reviews incompletely report methods for handling overlapping, discordant, and problematic data. J Clin Epidemiol. 2020;118:69\u201385.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"4872_CR51","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/EJE-11-0616","volume":"166","author":"W Wei","year":"2012","unstructured":"Wei W, Zhao H, Wang A, Sui M, Liang K, Deng H, Ma Y, Zhang Y, Zhang H, Guan Y. A clinical study on the short-term effect of Berberine in comparison to Metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012;166(1):99\u2013105.","journal-title":"Eur J Endocrinol"},{"issue":"7121","key":"4872_CR52","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature05485","volume":"444","author":"GS Hotamisligil","year":"2006","unstructured":"Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860\u20137.","journal-title":"Nature"},{"issue":"6","key":"4872_CR53","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/joim.12268","volume":"276","author":"D Grahame Hardie","year":"2014","unstructured":"Grahame Hardie D. AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J Intern Med. 2014;276(6):543\u201359.","journal-title":"J Intern Med"},{"key":"4872_CR54","doi-asserted-by":"crossref","unstructured":"Han Y, Xiang Y, Shi Y, Tang X, Pan L, Gao J, Bi R, Lai X. Pharmacokinetics and Pharmacological activities of Berberine in diabetes mellitus treatment. Evidence-based Complement Altern Med 2021.","DOI":"10.1155\/2021\/9987097"},{"issue":"1","key":"4872_CR55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.numecd.2016.11.122","volume":"27","author":"M Pirro","year":"2017","unstructured":"Pirro M, Vetrani C, Bianchi C, Mannarino MR, Bernini F, Rivellese AA. Joint position statement on nutraceuticals for the treatment of hypercholesterolemia of the Italian society of diabetology (SID) and of the Italian society for the study of arteriosclerosis (SISA). Nutr Metab Cardiovasc Dis. 2017;27(1):2\u201317.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1\u20132","key":"4872_CR56","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.mce.2012.08.006","volume":"363","author":"M Zhang","year":"2012","unstructured":"Zhang M, Lv X, Li J, Meng Z, Wang Q, Chang W, Li W, Chen L, Liu Y. Sodium Caprate augments the hypoglycemic effect of Berberine via AMPK in inhibiting hepatic gluconeogenesis. Mol Cell Endocrinol. 2012;363(1\u20132):122\u201330.","journal-title":"Mol Cell Endocrinol"},{"key":"4872_CR57","doi-asserted-by":"crossref","unstructured":"Barroso E, Jurado-Aguilar J, Wahli W, Palomer X, V\u00e1zquez-Carrera M. Increased hepatic gluconeogenesis and type 2 diabetes mellitus. Trends Endocrinol Metab 2024.","DOI":"10.1016\/j.tem.2024.05.006"},{"issue":"12","key":"4872_CR58","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.7150\/ijbs.62556","volume":"17","author":"Y Xu","year":"2021","unstructured":"Xu Y, Yu T, Ma G, Zheng L, Jiang X, Yang F, Wang Z, Li N, He Z, Song X, et al. Berberine modulates deacetylation of PPAR\u03b3 to promote adipose tissue remodeling and thermogenesis via AMPK\/SIRT1 pathway. Int J Biol Sci. 2021;17(12):3173\u201387.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"4872_CR59","first-page":"315","volume":"119","author":"RK Semple","year":"2009","unstructured":"Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, Vottero A, Kanabar D, Charlton-Menys V, Durrington P, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest. 2009;119(2):315\u201322.","journal-title":"J Clin Invest"},{"issue":"3","key":"4872_CR60","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1080\/13813455.2020.1869265","volume":"129","author":"B Al-Ani","year":"2023","unstructured":"Al-Ani B, Alzamil NM, Hewett PW, Al-Hashem F, Bin-Jaliah I, Shatoor AS, Kamar SS, Latif NSA, Haidara MA, Dawood AF. Metformin ameliorates ROS-p53-collagen axis of fibrosis and dyslipidemia in type 2 diabetes mellitus-induced left ventricular injury. Arch Physiol Biochem. 2023;129(3):734\u201340.","journal-title":"Arch Physiol Biochem"},{"issue":"4","key":"4872_CR61","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1734-1140(12)70883-6","volume":"64","author":"HB Xiao","year":"2012","unstructured":"Xiao HB, Sun ZL, Zhang HB, Zhang DS. Berberine inhibits dyslipidemia in C57BL\/6 mice with lipopolysaccharide induced inflammation. Pharmacol Rep. 2012;64(4):889\u201395.","journal-title":"Pharmacol Rep"},{"issue":"12","key":"4872_CR62","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1136\/gutjnl-2019-319745","volume":"69","author":"J Vily-Petit","year":"2020","unstructured":"Vily-Petit J, Soty-Roca M, Silva M, Raffin M, Gautier-Stein A, Rajas F, Mithieux G. Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease. Gut. 2020;69(12):2193\u2013202.","journal-title":"Gut"},{"issue":"3","key":"4872_CR63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","volume":"33","author":"AM Chao","year":"2023","unstructured":"Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023;33(3):159\u201366.","journal-title":"Trends Cardiovasc Med"},{"issue":"1\u20132","key":"4872_CR64","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cell.2013.12.016","volume":"156","author":"F De Vadder","year":"2014","unstructured":"De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, B\u00e4ckhed F, Mithieux G. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014;156(1\u20132):84\u201396.","journal-title":"Cell"},{"issue":"4","key":"4872_CR65","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.fertnstert.2023.07.025","volume":"120","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J. Recommendations from the 2023 international Evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023;120(4):767\u201393.","journal-title":"Fertil Steril"},{"issue":"12","key":"4872_CR66","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.tem.2020.09.002","volume":"31","author":"D Daneshjou","year":"2020","unstructured":"Daneshjou D, Soleimani Mehranjani M, Zadeh Modarres S, Shariatzadeh MA. Sitagliptin\/Metformin: A new medical treatment in polycystic ovary syndrome. Trends Endocrinol Metab. 2020;31(12):890\u20132.","journal-title":"Trends Endocrinol Metab"},{"key":"4872_CR67","doi-asserted-by":"publisher","first-page":"111468","DOI":"10.1016\/j.biopha.2021.111468","volume":"138","author":"SW Zhang","year":"2021","unstructured":"Zhang SW, Zhou J, Gober HJ, Leung WT, Wang L. Effect and mechanism of Berberine against polycystic ovary syndrome. Biomed Pharmacother. 2021;138:111468.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"4872_CR68","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nri3430","volume":"13","author":"N Kamada","year":"2013","unstructured":"Kamada N, Seo SU, Chen GY, N\u00fa\u00f1ez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13(5):321\u201335.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"4872_CR69","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jaci.2013.06.025","volume":"132","author":"RL Greer","year":"2013","unstructured":"Greer RL, Morgun A, Shulzhenko N. Bridging immunity and lipid metabolism by gut microbiota. J Allergy Clin Immunol. 2013;132(2):253\u201362. quiz 263.","journal-title":"J Allergy Clin Immunol"},{"key":"4872_CR70","doi-asserted-by":"publisher","first-page":"104722","DOI":"10.1016\/j.phrs.2020.104722","volume":"155","author":"S Habtemariam","year":"2020","unstructured":"Habtemariam S. Berberine Pharmacology and the gut microbiota: A hidden therapeutic link. Pharmacol Res. 2020;155:104722.","journal-title":"Pharmacol Res"},{"issue":"8","key":"4872_CR71","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.cell.2024.03.014","volume":"187","author":"C Li","year":"2024","unstructured":"Li C, Stra\u017ear M, Mohamed AMT, Pacheco JA, Walker RL, Lebar T, Zhao S, Lockart J, Dame A, Thurimella K, et al. Gut Microbiome and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria. Cell. 2024;187(8):1834\u2013e18521819.","journal-title":"Cell"},{"issue":"21","key":"4872_CR72","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","volume":"374","author":"S Yusuf","year":"2016","unstructured":"Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, L\u00f3pez-Jaramillo P, Leiter LA, Dans A, et al. Cholesterol Lowering in Intermediate-Risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021\u201331.","journal-title":"N Engl J Med"},{"key":"4872_CR73","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.phrs.2019.02.018","volume":"142","author":"W Anlu","year":"2019","unstructured":"Anlu W, Dongcheng C, He Z, Qiuyi L, Yan Z, Yu Q, Hao X, Keji C. Using herbal medicine to target the microbiota-metabolism-immunity axis as possible therapy for cardiovascular disease. Pharmacol Res. 2019;142:205\u201322.","journal-title":"Pharmacol Res"},{"issue":"27","key":"4872_CR74","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.3748\/wjg.v22.i27.6296","volume":"22","author":"AT Abegunde","year":"2016","unstructured":"Abegunde AT, Muhammad BH, Bhatti O, Ali T. Environmental risk factors for inflammatory bowel diseases: evidence based literature review. World J Gastroenterol. 2016;22(27):6296\u2013317.","journal-title":"World J Gastroenterol"},{"key":"4872_CR75","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/164_2016_122","volume":"239","author":"BP Abraham","year":"2017","unstructured":"Abraham BP, Ahmed T, Ali T. Inflammatory bowel disease: pathophysiology and current therapeutic approaches. Handb Exp Pharmacol. 2017;239:115\u201346.","journal-title":"Handb Exp Pharmacol"},{"issue":"Pt B","key":"4872_CR76","doi-asserted-by":"publisher","first-page":"111009","DOI":"10.1016\/j.intimp.2023.111009","volume":"124","author":"C Xu","year":"2023","unstructured":"Xu C, Zhao L, Zhou W, Li Y, Hu H, Wang Z. Synergistic effect of Berberine hydrochloride and dehydrocostus lactone in the treatment of ulcerative colitis: take gut microbiota as the target. Int Immunopharmacol. 2023;124(Pt B):111009.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"4872_CR77","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41574-020-00427-4","volume":"16","author":"F Bishehsari","year":"2020","unstructured":"Bishehsari F, Voigt RM, Keshavarzian A. Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer. Nat Rev Endocrinol. 2020;16(12):731\u20139.","journal-title":"Nat Rev Endocrinol"},{"key":"4872_CR78","doi-asserted-by":"publisher","first-page":"752512","DOI":"10.3389\/fmicb.2021.752512","volume":"12","author":"J Li","year":"2021","unstructured":"Li J, Li J, Ni J, Zhang C, Jia J, Wu G, Sun H, Wang S. Berberine relieves metabolic syndrome in mice by inhibiting liver inflammation caused by a High-Fat diet and potential association with gut microbiota. Front Microbiol. 2021;12:752512.","journal-title":"Front Microbiol"},{"key":"4872_CR79","doi-asserted-by":"crossref","unstructured":"Quesada-V\u00e1zquez S, Aragon\u00e8s G, Del Bas JM, Escot\u00e9 X. Diet, gut microbiota and Non-Alcoholic fatty liver disease: three parts of the same axis. Cells 2020, 9(1).","DOI":"10.3390\/cells9010176"},{"key":"4872_CR80","doi-asserted-by":"publisher","first-page":"105484","DOI":"10.1016\/j.phrs.2021.105484","volume":"167","author":"N Sodum","year":"2021","unstructured":"Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD\/NASH: targets and therapy. Pharmacol Res. 2021;167:105484.","journal-title":"Pharmacol Res"},{"issue":"3","key":"4872_CR81","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/ptr.6252","volume":"33","author":"M Imenshahidi","year":"2019","unstructured":"Imenshahidi M, Hosseinzadeh H. Berberine and barberry (Berberis vulgaris): A clinical review. Phytother Res. 2019;33(3):504\u201323.","journal-title":"Phytother Res"},{"key":"4872_CR82","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bbi.2020.10.003","volume":"91","author":"TT Nguyen","year":"2021","unstructured":"Nguyen TT, Kosciolek T, Daly RE, V\u00e1zquez-Baeza Y, Swafford A, Knight R, Jeste DV. Gut Microbiome in schizophrenia: altered functional pathways related to immune modulation and atherosclerotic risk. Brain Behav Immun. 2021;91:245\u201356.","journal-title":"Brain Behav Immun"},{"issue":"8","key":"4872_CR83","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41401-019-0212-1","volume":"40","author":"XM Liu","year":"2019","unstructured":"Liu XM, Zhao XM, Deng C, Zeng YP, Hu CH. Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway. Acta Pharmacol Sin. 2019;40(8):1049\u201357.","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"4872_CR84","doi-asserted-by":"publisher","first-page":"e93310","DOI":"10.1371\/journal.pone.0093310","volume":"9","author":"Y Hu","year":"2014","unstructured":"Hu Y, Young AJ, Ehli EA, Nowotny D, Davies PS, Droke EA, Soundy TJ, Davies GE. Metformin and Berberine prevent olanzapine-induced weight gain in rats. PLoS ONE. 2014;9(3):e93310.","journal-title":"PLoS ONE"},{"issue":"5","key":"4872_CR85","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s11684-019-0724-6","volume":"14","author":"D Song","year":"2020","unstructured":"Song D, Hao J, Fan D. Biological properties and clinical applications of Berberine. Front Med. 2020;14(5):564\u201382.","journal-title":"Front Med"},{"issue":"1","key":"4872_CR86","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13073-021-00927-6","volume":"13","author":"G Dong","year":"2021","unstructured":"Dong G, Feng J, Sun F, Chen J, Zhao XM. A global overview of genetically interpretable multimorbidities among common diseases in the UK biobank. Genome Med. 2021;13(1):110.","journal-title":"Genome Med"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-04872-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-025-04872-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-04872-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:34:53Z","timestamp":1757169293000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-025-04872-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4872"],"URL":"https:\/\/doi.org\/10.1186\/s12906-025-04872-4","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Affiliation 1 has been updated to have complete information details.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}